Literature DB >> 12510719

Selective photocoagulation in Coats' disease: ten-year follow-up.

P Nucci1, F Bandello, M Serafino, M E Wilson.   

Abstract

PURPOSE: The diagnostic hallmark of Coats' disease is development of "light bulb" telangiectasis in the retinal periphery, leading to posterior pole intraretinal and subretinal exudation. Even after complete obliteration of all abnormal vessels and resorption of all exudates, follow-up examinations are mandatory for several years.
METHODS: We retrospectively analyzed the charts, pictures and/or fluorescein angiographies of a series of 32 consecutive patients, in which the diagnosis of Coats' disease was made. All patients underwent selective photocoagulation of the telangiectasis using a yellow-dye laser. Efficacy of treatment was monitored with drawings and/or fluorescein angiographies.
RESULTS: All our patients had unilateral disease, with macular involvement and exudative retinal detachment. Visual acuity improved in one patient, decreased from light perception to blindness in another, and was unchanged in the remainder.
CONCLUSIONS: This is the first report of anatomical benefits from treatment with a yellow-dye laser (i.e., selective photocoagulation without cryotherapy or drainage) despite the presence of a severe form of Coats' disease. Our young Coats' patients responded quickly to treatment. With successful obliteration of the abnormal vasculature, exudates began to absorb in about 4 to 8 weeks although, in some cases, 10 to 12 months were needed to obtain resolution of the exudative detachment. Poor visual outcome of 20/100 or worse was common. In Coats' patients, the key issue is continuous control and long-term follow-up.

Entities:  

Mesh:

Year:  2002        PMID: 12510719

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  11 in total

1.  Coats' disease: not such a smooth ride.

Authors:  Paolo Nucci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-07       Impact factor: 3.117

2.  Observations on the management of Coats' disease: less is more.

Authors:  Robert S Adam; Peter J Kertes; Wai-Ching Lam
Journal:  Br J Ophthalmol       Date:  2006-10-04       Impact factor: 4.638

3.  Coats' disease: an Indian perspective.

Authors:  Pukhraj Rishi; Ekta Rishi; Mahesh Uparkar; Tarun Sharma; Lingam Gopal; Pramod Bhende; Muna Bhende; Pratik Ranjan Sen; Parveen Sen
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

4.  Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium.

Authors:  Young Sun; Atul Jain; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-07       Impact factor: 3.117

5.  The management of "coats' response" in a patient with x-linked retinitis pigmentosa-a case report.

Authors:  Shveta Bansal; Niladri Saha; W H Woon
Journal:  ISRN Surg       Date:  2011-04-20

6.  Treatment of stage 3 Coats' disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach.

Authors:  Xuan Cai; Peiquan Zhao; Qi Zhang; Haiying Jin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-21       Impact factor: 3.117

7.  Coats' Disease: Very Long-Term Outcome After Early Stage Conventional Treatment.

Authors:  Salvatore Perrone; Alberto Rossetti; Patrick Sportiello; Pierfrancesco Mirabelli; Pierangela Cimatti; Daniele Doro
Journal:  Open Ophthalmol J       Date:  2016-02-29

8.  Factors Predictive of Subretinal Fluid Resolution in Coats Disease: Analysis of 177 Eyes in 177 Patients at a Single Center.

Authors:  Chloe T L Khoo; Lauren A Dalvin; Li-Anne S Lim; Mehdi Mazloumi; Hatice T Atalay; Sanika Udyaver; Jerry A Shields; Carol L Shields
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Jul-Aug

9.  Experience with Intravitreal Ranibizumab as an Adjunct to Ablation Therapy in Eyes with Exudative Coats' Disease.

Authors:  Mohamed Nowara; Yousef A Fouad; Ihab Abdel Aziz; Ahmed M Habib; Mariam Al-Feky; Hisham Hassan
Journal:  Clin Ophthalmol       Date:  2021-01-29

10.  Coats' disease: characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease.

Authors:  Yacoub A Yousef; Ahmad H ElRimawi; Rashed M Nazzal; Ahmad F Qaroot; Adnan H AlAref; Mona Mohammad; Omar Abureesh; Robert Rejdak; Katarzyna Nowomiejska; Teresio Avitabile; Mario Damiano Toro; Ibrahim AlNawaiseh
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.